Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Ранг среди акций #7142
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Цена акции
$40.39
Последняя синхронизация: 2023-08-18
Рыночная капитализация
$1.70B
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля Chinook Therapeutics, Inc. (KDNY)

Категория

Коэффициент P/S для Chinook Therapeutics, Inc. (KDNY)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Chinook Therapeutics, Inc., текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для Chinook Therapeutics, Inc. с 2026 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
Недостаточно данных для указанных дат.
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH